GlaxoSmithKline’s Neutral Rating Reaffirmed at Citigroup Inc. (GSK)
GlaxoSmithKline (NYSE:GSK)‘s stock had its “neutral” rating restated by Citigroup Inc. in a research note issued on Wednesday, AnalystRatingsNetwork reports.
Shares of GlaxoSmithKline (NYSE:GSK) opened at 54.81 on Wednesday. GlaxoSmithKline has a 52-week low of $43.68 and a 52-week high of $55.07. The stock has a 50-day moving average of $52.96 and a 200-day moving average of $51.94. The company has a market cap of $131.3 billion and a price-to-earnings ratio of 15.25.
GlaxoSmithKline (NYSE:GSK) last released its earnings data on Wednesday, February 5th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.30. The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.84 billion. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. Analysts expect that GlaxoSmithKline will post $3.73 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a dividend of $0.7496 per share. This represents a $3.00 dividend on an annualized basis and a yield of 5.48%. The ex-dividend date of this dividend is Wednesday, February 19th.
Several other analysts have also recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Friday, February 7th. They now have a $55.00 price target on the stock. Separately, analysts at S&P Equity Research upgraded shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research note on Monday, January 27th. Finally, analysts at Berenberg Bank downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, January 24th. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $88.67.
GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.